Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

Transaction adds TYMLOS ® to portfolio alongside NUZYRA ® and XHANCE ® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced the completion of its combination with Radius Health, Inc., adding the osteoporosis therapy TYMLOS® (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines.